However, anti-PD1 treatment alone significantly increased numbers of CD8+PD1+ T cells, this effect being recently reported by Pfister et al9 who suggested this T cell phenotype compromises the efficacy of anti-PD1 treatment in NASH-HCC (online supplemental figure 4C). This evidence concerns the gene CD8A and hepatocellular carcinoma.